Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application. Chengchao Ding, Darshit Patel, Yunjing Ma, Jamie F. S. Mann, Jianjun Wu, and Yong Gao*. Front Immunol. 2021 Jul 20;12:697683. IF : 7.562. 期刊论文
Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 vaccine. The major obstacle to the development of HIV-1 vaccine is the extreme diversity of viral genome sequences. Nonetheless, a number of broadly neutralizing antibodies (bNAbs) against HIV-1 have been made and identified in this area. Novel strategies based on using these bNAbs as an efficacious preventive and/or therapeutic intervention have been applied in clinical. In this review, we summarize the recent development of bNAbs and its application in HIV-1 acquisition prevention as well as discuss the innovative approaches being used to try to convey protection within individuals at risk and being treated for HIV-1 infection.
上一篇：Digital PCR assay for the effective detection of COVID-19 patients with SARS-CoV-2 low viral load. 1. Sun Y#, Ding C#, Chen Q, Xie J, Yu J, Shi Y, Jiang C, Zhang Z, He H, Ge Y, Li W, He J*, Gao Y*. J Virol Methods. 2021 Sep;295:114185. 期刊论文
下一篇：Crucial mutation of spike protein evolved to variant SARS-CoV-2 escape the neutralization of convalescent plasma and RBD-specific monoclonal antibodies. Chengchao Ding, Jun He, Xiangyu Zhang, ChengCheng Jiang, Yong Sun, Yuqing Zhang, Qingqing Chen, Hongliang He, Wenting Li, Jiajia Xie*, Zhirong Liu* Yong Gao*. Frontiers in Immunology. 2021 Aug 17;12:693775. 期刊论文. IF: 7.562. 2021 Aug 17;12:693775. 期刊论文